- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07221955
O Impacto do Qualia Glutathione+ nos Níveis de Glutationa no Sangue
O Impacto do Qualia Glutationa+ nos Níveis de Glutationa no Sangue
This is a double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be assigned to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.
Visão geral do estudo
Status
Descrição detalhada
Note on allocation (added September 2026): Participants were assigned to study arms by systematic allocation rather than by random allocation. Earlier versions of this record described the design as randomized. The Allocation field and the design descriptions were corrected to Non-Randomized to reflect the method actually used. No other aspect of the study design, conduct, or analysis changed.
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
California
-
Carlsbad, California, Estados Unidos, 92011
- Qualia Life Sciences
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion criteria:
- Provide voluntary, written, informed consent to participate in the study
- Agree to provide a valid cell phone number and are willing to receive communications through text
- Can read and write English
- Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly
- Willing to complete questionnaires, records, and diaries associated with the study.
- Healthy male and female participants aged 45-75 years
- Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20)
- Willing to avoid starting new or stopping any existing dietary supplements throughout the study
Exclusion criteria:
- Women who are pregnant, breastfeeding, or planning to become pregnant during the trial
- Known food intolerances/allergy to any ingredients in the product
- Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer
- Having had a significant cardiovascular event in the past 6 months
- Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines
- On immunosuppressive therapy
- Adults lacking capacity to consent
- Active Smokers
- Diagnosed Diabetics
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Outro
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: Qualia Glutathione+ version 1
Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences |
Qualia Glutathione+ version 1 manufactured by Qualia Life Sciences |
|
Comparador Ativo: Qualia Glutathione+ version 2
Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences |
Qualia Glutathione+ version 2 manufactured by Qualia Life Sciences |
|
Comparador de Placebo: Placebo
Rice flour placebo |
Rice flour |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Total Glutathione levels from baseline to Day 20
Prazo: 0-20 days
|
To assess between-group differences in the change in blood Total Glutathione levels from baseline to Day 20 following supplementation with Qualia Glutathione version 1 versus placebo and Qualia Glutathione version 2 versus placebo |
0-20 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
between-group differences in blood Total Glutathione levels
Prazo: baseline to day 20
|
To assess the between-group differences in blood Total Glutathione levels from baseline to Day 20 following supplementation between Qualia Glutathione version 1 and Qualia Glutathione version 2. |
baseline to day 20
|
|
within-group differences in the change in blood Glutathione levels
Prazo: baseline to day 20
|
To assess within-group differences in the change in blood Glutathione levels |
baseline to day 20
|
|
Safety and Tolerability survey
Prazo: baseline to days 7, 14 and 20
|
To evaluate side effect profiles using a custom Safety and Tolerability survey. |
baseline to days 7, 14 and 20
|
|
PROMIS Global Health-10
Prazo: baseline to days 7, 14 and 20
|
The PROMIS® Global Health Scale v1.2 (also known as the PROMIS-GH or PROMIS-10) is a 10-item, non-disease-specific questionnaire for adults to assess general physical and mental health. It yields two main scores, a Global Physical Health (GPH) T-score and a Global Mental Health (GMH) T-score, derived from four items each, to understand overall health perceptions. The scale is widely translated and free for use in clinical and research settings.
|
baseline to days 7, 14 and 20
|
|
PROMIS Short Form v1.0 - Fatigue 10a
Prazo: baseline to days 7, 14 and 20
|
The PROMIS Fatigue item banks assess a range of self-reported symptoms, from mild subjective feelings of tiredness to an overwhelming, debilitating, and sustained sense of exhaustion that likely decreases one's ability to execute daily activities and function normally in family or social roles. Fatigue is divided into the experience of fatigue (frequency, duration, and intensity) and the impact of fatigue on physical, mental, and social activities. The fatigue short forms are universal rather than disease-specific. All assess fatigue over the past seven days. Raw Score Minimum and Maximum: 10-50 the lower the better |
baseline to days 7, 14 and 20
|
|
PROMIS Cognitive Function - Short Form 8a
Prazo: baseline to days 7, 14 and 20
|
The PROMIS Cognitive Function v2.0 - Short Form 8a is an 8-item self-report questionnaire designed to assess perceived cognitive function over the past seven days. It measures difficulties in areas such as forming thoughts, concentration, attention, thinking speed, memory, and the ability to shift between tasks. - Raw Score Minimum and Maximum: 8-40 - The higher the score, the better |
baseline to days 7, 14 and 20
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
- QLS-019
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .